International Immunopharmacology, Год журнала: 2024, Номер 146, С. 113788 - 113788
Опубликована: Дек. 19, 2024
Язык: Английский
Cardiovascular Drugs and Therapy, Год журнала: 2024, Номер unknown
Опубликована: Март 16, 2024
Abstract While oncotherapy has made rapid progress in recent years, side effects of anti-cancer drugs and treatments have also come to the fore. These include cardiotoxicity, which can cause irreversible cardiac damages with long-term morbidity mortality. Despite continuous in-depth research on drugs, an improved knowledge underlying mechanisms cardiotoxicity are necessary for early detection management risk. Although most reviews focus cardiotoxic effect a specific individual chemotherapeutic agent, aim our review is provide comprehensive insight into various agents that induced their mechanisms. Characterization these underpinned by animal models clinical studies. In order gain complex mechanisms, we emphasize role inflammatory processes oxidative stress chemotherapy-induced changes. A better understanding identification interplay between chemotherapy inflammatory/oxidative hold some promise prevent or at least mitigate cardiotoxicity-associated mortality among cancer survivors.
Язык: Английский
Процитировано
10
Frontiers in Pharmacology, Год журнала: 2024, Номер 15
Опубликована: Март 20, 2024
Significant advances in chemotherapy drugs have reduced mortality patients with malignant tumors. However, chemotherapy-related cardiotoxicity increases the morbidity and of patients, has become second leading cause death after tumor recurrence, which received more attention recent years. Arrhythmia is one common types chemotherapy-induced cardiotoxicity, a new risk related to treatment, seriously affects therapeutic outcome patients. Traditional Chinese medicine experienced thousands years clinical practice China, accumulated wealth medical theories treatment formulas, unique advantages prevention diseases. may reduce arrhythmic toxicity caused by without affecting anti-cancer effect. This paper mainly discussed pathogenesis secondary chemotherapeutic drug-induced arrhythmia (CDIA), summarized studies on compounds, Combination Formula injection that be beneficial intervention CDIA including atrial fibrillation, ventricular sinus bradycardia, order provide reference for arrhythmias.
Язык: Английский
Процитировано
4
Steroids, Год журнала: 2025, Номер 214, С. 109563 - 109563
Опубликована: Янв. 31, 2025
Язык: Английский
Процитировано
0
Cardiovascular Drugs and Therapy, Год журнала: 2025, Номер unknown
Опубликована: Фев. 15, 2025
Язык: Английский
Процитировано
0
The Egyptian Heart Journal, Год журнала: 2025, Номер 77(1)
Опубликована: Март 10, 2025
Abstract Background Cardiomyopathy is a heterogeneous group of myocardial disorders characterized by structural and functional abnormalities the heart muscle. It classified into primary (genetic, mixed, or acquired) secondary categories, resulting in various phenotypes including dilated, hypertrophic, restrictive patterns. Hypertrophic cardiomyopathy, most common form, can cause exertional dyspnea, presyncope, sudden cardiac death. Dilated cardiomyopathy typically presents with failure symptoms, while rarer often associated systemic diseases. Diagnosis involves comprehensive evaluation history, physical examination, electrocardiography, echocardiography. Treatment options range from pharmacotherapy lifestyle modifications to implantable cardioverter-defibrillators transplantation refractory cases. Main body Anthracyclines, particularly doxorubicin, have emerged as crucial components cancer treatment, demonstrating significant antitumor activity across malignancies. These drugs become standard numerous chemotherapy regimens, improving patient outcomes. However, their use severe cardiotoxicity, failure. The mechanisms anthracycline action toxicity are complex, involving DNA damage, iron-mediated free radical production, disruption cardiovascular homeostasis. Doxorubicin-induced (DIC) complication treatment poor prognosis limited effective treatments. pathophysiology DIC multiple mechanisms, oxidative stress, inflammation, mitochondrial calcium homeostasis disorder. Despite extensive research, no for established currently available. Dexrazoxane only FDA-approved protective agent, but it has limitations. Recent studies explored potential therapeutic approaches, natural drugs, endogenous substances, new dosage forms, herbal medicines. lack experimental models incorporating pre-existing limits understanding efficacy. Conclusion Cardiomyopathy, whether secondary, poses clinical challenge due its varying etiologies advanced stages. Anthracycline-induced chemotherapy, doxorubicin being notable contributor. advancements therapies, cardiotoxic effects anthracyclines necessitate further investigation preventive strategies interventions improve
Язык: Английский
Процитировано
0
Medical Oncology, Год журнала: 2024, Номер 41(8)
Опубликована: Июль 8, 2024
Abstract Cardiotoxicity is a side effect of chemotherapy in human epidermal growth factor receptor 2 (HER2) positive breast cancer patients receiving both anthracyclines and trastuzumab. We looked for possible protective rosuvastatin against chemotherapy-induced cardiotoxicity. Methods: 50 newly diagnosed HER2 were randomly allocated into two groups: 25patients each. Group 1(control group) received doxorubicin 4 cycles (3 months) followed by trastuzumab adjuvant therapy. (treatment therapy 20 mg oral 24 h before the first cycle once daily rest follow-up period (6 months). Transthoracic echocardiography was done, blood samples collected initiation therapy, after 3 months 6 to assess serum levels high sensitivity cardiac troponin I (hs-cTnI), Myeloperoxidase (MPO), Interleukin-6 (IL-6) Alanine aminotransferase (ALT). The study retrospectively registered Clinical Trials.gov April 2022. Its ID NCT05338723. Compared control group, Rosuvastatin-treated group had significantly lower decline LVEF months. They Hs-cTnI IL-6 months, MPO Four experienced cardiotoxicity while no one rosuvastatin-treated group. Rosuvastatin attenuated cardiotoxicity, so it promising agent
Язык: Английский
Процитировано
3
Pharmaceuticals, Год журнала: 2024, Номер 17(1), С. 93 - 93
Опубликована: Янв. 10, 2024
Doxorubicin (DOX) is an incessantly used chemotherapeutic drug that can cause detrimental dose-dependent effects such as cardiotoxicity and congestive heart failure. Hence, there a need to discover innovative therapeutic approaches counteract DOX-induced (DIC). MSC-Exos have shown reduce apoptosis cardiac fibrosis promote cardiomyocyte proliferation in myocardial infracted mice. However, the effect of on ameliorating pyroptosis has not been investigated. In this current study, H9c2 were first exposed DOX stimulate pyroptosis, followed by subsequent treatment with MSC-Exos, further analysis performed through immunocytochemistry, western blotting, RT-PCR. Our data depicted post-treatment significantly (p < 0.05) reduced HMGB1/TLR4 axis, inflammasome formation (NLRP3), pyroptotic markers (caspase-1, IL-1β, IL-18), executioner (GSDMD) DOX-treated cells. conclusion, our show attenuates inflammation-induced vitro DIC model. findings indicate may serve promising intervention for mitigating DIC, they maintain capabilities MSCs while circumventing drawbacks associated traditional stem cell therapy.
Язык: Английский
Процитировано
2
Chemico-Biological Interactions, Год журнала: 2024, Номер 401, С. 111155 - 111155
Опубликована: Июль 17, 2024
Язык: Английский
Процитировано
2
Biology, Год журнала: 2024, Номер 13(9), С. 689 - 689
Опубликована: Сен. 3, 2024
Anthracyclines represent a highly efficacious class of chemotherapeutic agents employed extensively in antitumor therapy. They are universally recognized for their potency treating diverse malignancies, encompassing breast cancer, gastrointestinal tumors, and lymphomas. Nevertheless, the accumulation anthracyclines within body can lead to significant cardiac toxicity, adversely impacting both survival rates quality life tumor patients. This limitation somewhat restricts clinical utilization. Determining how monitor mitigate cardiotoxicity at an early stage has become urgent problem be solved. Therefore, this paper reviews mechanism action, monitoring, strategies prevention anthracycline-induced reference.
Язык: Английский
Процитировано
2
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(17), С. 9735 - 9735
Опубликована: Сен. 9, 2024
Doxorubicin (DOX), a commonly used anticancer agent, causes cardiotoxicity that begins with the first dose and may progress to heart failure years after treatment. An inflammatory response associated neutrophil recruitment has been recognized as mechanism of DOX-induced cardiotoxicity. This study aimed validate mRNA expression previously identified biomarkers cardiotoxicity, PGLYRP1, CAMP, MMP9, CEACAM8, assay their protein in peripheral blood breast cancer patients. Blood samples from 40 patients treated DOX-based chemotherapy were collected before cycle > 2 The gene PGLYRP1/Tag7, CAMP/LL37, MMP9/gelatinase B, CEACAM8/CD66b determined using ELISA reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Receiver operating characteristic (ROC) curve analysis was determine diagnostic value each candidate biomarker. Patients (n = 20) had significantly elevated levels CEACAM8 at baseline, chemotherapy, treatment relative without 20). DOX induced higher all examined both groups At post treatment, but MMP9 dropped below baseline. There good correlation between target proteins. We demonstrate circulating can predict DOX. novel finding be early identification risk for
Язык: Английский
Процитировано
2